UK markets close in 1 hour 34 minutes

Genfit SA (GNFTF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
4.12000.0000 (0.00%)
As of 09:30AM EDT. Market open.

Genfit SA

Parc EurasantE
885, avenue EugEne AvinEe
Loos 59120
France
33 3 20 16 40 00
https://www.genfit.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees134

Key executives

NameTitlePayExercisedYear born
Mr. Jean-Francois MouneyCo-Founder & Chairman331.88kN/A1955
Mr. M. Pascal PrigentChief Exec. Officer502.94kN/A1968
Prof. Bart StaelsCo-Founder & Chairman of the Scientific Advisory BoardN/AN/A1963
Mr. Thomas BaetzChief Financial OfficerN/AN/A1974
Mr. Pascal CaiseyChief Operating OfficerN/AN/A1968
Dr. Dean W. Hum Ph.D.Chief Scientific OfficerN/AN/A1962
Mr. Laurent LannooCorp. Sec. & Director of Legal AffairsN/AN/A1970
Ms. Stefanie MagnerChief Compliance Officer & VP of International Legal AffairsN/AN/A1981
Ms. Emilie DesodtVice-Pres of HRN/AN/A1983
Mr. Jean-Christophe MarcouxChief Strategy OfficerN/AN/A1977
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Corporate governance

Genfit SA’s ISS governance QualityScore as of 1 October 2022 is 8. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.